Physical activity, nutritional status and systemic inflammation in COPD

Laveneziana, Pierantonio; Palange, Paolo

doi:10.1183/09031936.00041212

Cited by 48 publications

(35 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another hypothesis supports the proposition that an enhanced expression of granulocyte-macrophage colony-stimulating factor and IL-6 in COPD plays an important role, as these mediators stimulate neutrophils release from the bone marrow causing an increased neutrophil amount in the peripheral blood [7], [8] . Systemic hypoxia due to progression of COPD has been suggested as a possibility [2] .…”

Section: Introductionsupporting

confidence: 61%

Evaluation of Circulating Protein Biomarkers of Inflammation in COPD

Jaswal¹

2017

jmscr

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 61%

Evaluation of Circulating Protein Biomarkers of Inflammation in COPD

Jaswal¹

2017

jmscr

View full text Add to dashboard Cite

show abstract

“…Patologie te z kolei są czynnikami ryzyka wystąpienia chorób sercowo-naczyniowych [48]. Obniżona aktywność ruchowa u części pacjentów z POChP także może wiązać się z rozwojem cukrzycy oraz patologii naczyniowych [49,50].…”

Section: Patogeneza Współistnienia Pochp I Chorób Sercowo-naczyniowychunclassified

Przewlekła Obturacyjna Choroba Płuc i Choroby Sercowo-Naczyniowe—“Kontinuum Sercowo-PłUcne”

Batura‐Gabryel¹,

Grabicki²

2014

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Przewlekła obturacyjna choroba płuc i choroby sercowo--naczyniowe -"kontinuum sercowo-płucne"Chronic obstructive pulmonary disease and cardiovascular diseases -'cardiopulmonary continuum' Praca nie była finansowana AbstractChronic obstructive pulmonary disease (COPD) is characterised by persistent airflow limitation and extrapulmonary comorbidities, which contribute to the overall severity. Some risk factors, with tobacco smoking as the most serious one, lead to a chronic, systemic inflammation that plays the main role in the pathogenesis of COPD and comorbidities, including cardiovascular diseases (CVD). The course of COPD is diverse; it depends on pathologies in the respiratory system and on other organ dysfunctions. CVDs are the most commonly recognised comorbidities in COPD patients. The severity and natural course of COPD, as well as quality of the patient's life, are influenced by them. CVDs are frequently the reason for hospitalisation and may lead to death. They are also an important prognostic factor. Comorbidities may prolong exacerbation of COPD. On the other hand, COPD is an independent risk factor of CVD. The prevalence of COPD is high in patients suffering from coronary artery disease, and airflow limitation is a major risk factor for chronic heart failure. These complex interactions between heart and lung can be denoted as 'cardiopulmonary continuum'. These dependencies are not recognised in detail. Currently research is being done, which attempts to explain these complicated relations. For many years COPD and CVD were not connected. Today it is known that patients suffering from COPD must be provided comprehensive care. It is necessary to monitor the risk of CVD and their influence on the COPD course. Careful and proper treatment of all diseases is essential. An interdisciplinary team with good cooperation should prepare a plan of COPD treatment with simultaneous therapy of comorbidities. Key words: COPD, cardiovascular diseases, comorbiditiesPneumonol. Alergol. Pol. 2014; 82: 590-596 StreszczeniePrzebieg przewlekłej obturacyjnej choroby płuc (POChP) charakteryzuje się nie tylko utrzymującymi się ograniczeniami przepływu powietrza przez oskrzela, ale również współwystępowaniem patologii pozapłucnych. Czynniki ryzyka, w tym przede wszystkim palenie tytoniu, prowadzą do rozwoju przewlekłego, ogólnoustrojowego procesu zapalnego, który pełni główną rolę w patogenezie zarówno POChP, jak i wielu chorób towarzyszących, w tym sercowo-naczyniowych. Obraz kliniczny POChP jest różnorodny i zależy od nasilenia zmian w układzie oddechowym, jak również od dysfunkcji innych narządów i chorób współistniejących. U osób z chorobą obturacyjną płuc najczęściej obserwuje się współwystępowanie chorób układu sercowo-naczyniowego, które wpływają na jej ciężkość i przebieg naturalny, na jakość życia chorych oraz wielokrotnie są przyczyną hospitalizacji i zgonu. Są również ważnym czynnikiem prognostycznym. Obecność dodatkowych chorób może przedłużać zaostrzenie POChP. Z drugiej strony POChP jest niezależnym czynnikiem ryz...

show abstract

“…One systematic review found that dietary supplementation improved body weight and grip strength [225], whereas another systematic review found nonsignificant trends toward a beneficial effect of nutritional supplementation on anthropometric measures, lung function and exercise capacity [226]. Alternative metabolic treatments, including androgens and human growth hormone, have also been tried, but their long-term effects remain unknown [227]. Micronutrients may also play a role in COPD.…”

Section: Nutritionmentioning

confidence: 99%

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

et al. 2015

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and resource use worldwide. The goal of this official American Thoracic Society (ATS)/European Respiratory Society (ERS) research statement is to describe evidence related to diagnosis, assessment and management; identify gaps in knowledge; and make recommendations for future research. It is not intended to provide clinical practice recommendations on COPD diagnosis and management.Clinicians, researchers, and patient advocates with expertise in COPD were invited to participate. A literature search of Medline was performed, and studies deemed relevant were selected. The search was not a systematic review of the evidence. Existing evidence was appraised and summarised, and then salient knowledge gaps were identified.Recommendations for research that addresses important gaps in the evidence in all areas of COPD were formulated via discussion and consensus.Great strides have been made in the diagnosis, assessment and management of COPD, as well as understanding its pathogenesis. Despite this, many important questions remain unanswered. This ATS/ ERS research statement highlights the types of research that leading clinicians, researchers, and patient advocates believe will have the greatest impact on patient-centred outcomes. @ERSpublications ATS/ERS statement: which types of research will have the greatest future impact on patientcentred outcomes in COPD? http://ow.ly/I54Hb

show abstract

Physical activity, nutritional status and systemic inflammation in COPD

Abstract: [No abstract available

Cited by 48 publications

References 112 publications

Evaluation of Circulating Protein Biomarkers of Inflammation in COPD

Evaluation of Circulating Protein Biomarkers of Inflammation in COPD

Przewlekła Obturacyjna Choroba Płuc i Choroby Sercowo-Naczyniowe—“Kontinuum Sercowo-PłUcne”

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

Contact Info

Product

Resources

About